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Coronavirus: Where Has All the Health Economics Gone?
Cam Donaldson1* ID , Craig Mitton2
Abstract
As the coronavirus disease 2019 (COVID-19) pandemic continues to unfold there is an untold number of trade-offs 
being made in every country around the globe. The experience in the United Kingdom and Canada to date has not seen 
much uptake of health economics methods. We provide some thoughts on how this could take place, specifically in three 
areas. Firstly, this can involve understanding the impact of lockdown policies on national productivity. Secondly, there 
is great importance in studying trade-offs with respect to enhancing health system capacity and the impact of the mix of 
private-public financing. Finally, there are key trade-offs that will continue to be made both in terms of access to testing 
and ventilators which would benefit greatly from economic appraisal. In short, health economics could – and we would 
argue most certainly should – play a much more prominent role in policy-making as it relates to the current as well as 
future pandemics.
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Introduction
As debates unfold about how coronavirus and coronavirus 
disease 2019 (COVID-19) have challenged evidence-based 
medicine,1 the same might apply to health economics. Apart 
from being seen as a branch of disease modelling, which itself 
has been recognised as an inexact science,2 health economics 
seems to have been absent from important debates based on its 
lifeblood of resource scarcity, and consequent trade-offs, each 
of which have been laid bare in the current crisis. This seems 
even more contradictory when two of the basic structures of 
society – health and the economy – are each threatened, but 
with the discipline connecting the two – health economics – 
not represented at top tables of advice.3-8 Even more, given the 
undoubted world-leading recognition of health economics in 
some of the worst-affected countries. 
Health economists may not have been welcome, or thought 
of, at the outset of this crisis. When throwing everything you 
have at a major existential problem, it is not good to have a 
branch of the ‘dismal science’ sitting in the room saying “Wait 
a minute….Hold on…?” But, with public health leaders 
and other clinical experts having done their best to flatten 
the curve, it is timely to reflect on what health economics 
might offer in advance of, within and in emerging from such 
pandemics. This is about health economics in its broadest 
sense; as much a branch of moral philosophy, laying out issues 
arising from trade-offs being made, as a quantifier of costs 
and benefits of specific costs and benefits from such trade-
offs. So, what might these trade-offs be, and what approach 
might health economists take to thinking about and analysing 
them? 
Health Versus the Economy? Only “at the Margin”
‘Guns versus butter’ has been invoked on many occasions by 
politicians in the past to show the large-scale trade-offs that 
societies have to make in times of crisis; usually in wartime. 
COVID-19 has brought this large-scale type of question to 
light in terms of health versus the economy. This may seem 
straightforward at first sight. What might be the benefits gained 
– in lives saved, years of life saved or quality adjusted life years 
saved – from the increased healthcare expenditures and the 
social and economic support packages thrown at COVID-19 
by various governments? This should include assessment 
of the opportunity cost of patients whose procedures and 
treatments were curtailed. However, also of great importance, 
and less straightforward, is examining first the fall in national 
productivity that will ensue – and has already ensued – from 
lockdown policies, and second, as healthcare spending is 
directly linked to gross domestic product, future economic 
downturn resulting in spending less on healthcare and social 
care and other key support services in years to come, were this 
to transpire. This should be possible to model.9 
Such models are likely to emerge after the fact, and could 
lead to health economists being accused of explaining what 
happened when it is too late but having had little to say as 
the crisis unfolds; as was largely the case with our parent 
discipline of economics back in 2008. But there is a clear 
opportunity for the use of economics, through ‘marginal 
analysis’ - that is, in considering trade-offs across health and 
the economy as we go. Currently, governments are presenting 
the easing of lockdown as a win-win, ie, easing lockdown for 
low-risk economic activities as long as there is no threat to the 
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R-value of disease spread. However, in short order, genuine 
trade-offs will emerge which will result in us posing questions 
such as “how much might we allow the R-value and the death 
toll to rise for gains in economic activity?” In other words, 
and inescapably, what is the value of life? Estimates of such 
values exist for use in policy-making,10,11 and it is a question 
to which economists could contribute through further work 
on public preferences and on modelling values revealed by the 
policy choices made at the margin in this particular context. 
It is clear that trade-offs and choice making are at the very 
heart of health economics. If one is to rely only on (at times 
unfounded) epidemiological models, it is impossible to assess 
the value of a given set of actions (ie, costs relative to benefits) 
and thus the decision-maker does not possess adequate 
information to determine how best to allocate limited societal 
resources.
On the evening news, we started by seeing Finance 
Ministers providing updates on aid packages and the economy 
as a whole while Health Ministers independently have given 
the latest COVID-19 case counts. Models are possibly being 
constructed in the background, but do those for the economy 
link back across to health, and vice versa, in ways that a health 
economist might suggest? Now, we are moving towards the 
trade-offs outlined, and it appears, at least in both the United 
kingdom and Canada, to be happening without drawing on 
the health economics methods at hand. 
Health for the Economy: Preparedness, Capacity and Public-
Private Mix
This year, the LSE-Lancet Commission of the Future of the 
NHS (National Health Service) was due to report against 
a backdrop considerable strain on health and social care 
resources.12 COVID-19 has raised the stakes even further, 
especially in light of the economic outlook. Nevertheless, 
if not instantly, economies will recover, and longer-term 
questions of preparedness of health and social care systems 
post-COVID-19 will remain. More specifically, these are 
about capacity and public-private mix.
With respect to capacity, South Korea and Germany are 
currently being held out as models, particularly in terms of 
abilities to test and isolate early. There could, of course, be 
other factors at play, such as societal cultures more responsive 
to government advice. But, part of the reckoning will involve 
asking what is it about their healthcare systems that allowed 
them to react so effectively. A clue might be in the usual 
operating capacities of such systems. For example, the UK’s 
NHS consistently functions at over 90% bed occupancy, giving 
us little room to address the peaks in required access during 
such crises.13 Similarly, in British Columbia, the western most 
Province in Canada, some 15 000 surgeries were cancelled 
over a four-week period from mid-March to mid-April to 
clear the way for the anticipated COVID-19 surge (which has 
yet to arrive). Germany spends more on its publicly-funded 
healthcare system than most other countries of the world, 
frequently operating at around 80% bed occupancy.14 Did 
this, somehow, give Germany the capacity to marshal the 
right facilities at the right time to combat the virus? If so, what 
would be the cost of getting to this level of capacity in the 
UK or Canada? Not only should this be characterised simply 
as a ‘cost,’ but rather an investment in the form of insurance 
(ie, surge protection). Classic health economics methods such 
as cost-effectiveness analysis or cost-utility analysis can be 
brought to the fore here to help inform decision-making. As 
opposed to health vs. the economy, would such ‘investment’ 
in capacity have avoided the economic (and health) pain to 
come? Experiences of different countries should inform this, 
demonstrating that, rather than competing with each other, 
health and the economy are in fact mutually dependent.15 
Again, from our perspective the question of system capacity 
is fundamentally one of trade-offs to which health economics 
is uniquely positioned to contribute to in terms of assessing 
what amount of surge protection is warranted relative to other 
spends of the limited resources.
As outsiders looking in, in our view the public-private 
mix is even more of an issue for the United States. The key, 
here, in a Presidential election year, is how the US public 
view the efforts of more-coordinated single-payer systems in 
dealing with the virus. Despite caveats about demographics, 
different stages of progression of COVID-19 across countries 
and their different cultures, it would seem that not only the 
ultra-interventionist state of China but also the freer societies 
with single-payer health systems mentioned above have been 
better able to organise testing, isolation and treatment as well 
as behavioural initiatives required to fight coronavirus. In the 
United States, the public might well be asking if their own 
system somehow lacks the ability to organise in such similar 
ways, despite being, by far, the highest spender on health 
services in the world. Ironically, the call of Governor Andrew 
Cuomo of New York on March 31, 2020 to bring it all together,16 
revealed quite blatantly that the word ‘system’ is a misnomer 
for US healthcare. It comprises several systems encompassing 
private insurance, the Veterans Administration, Medicare and 
Medicaid, amongst others, much of which operates without 
integration with primary care or public health which may 
have contributed to unfolding disaster in New York City. 
Might this now be the time? Has coronavirus shown the US 
population another advantage of predominantly publicly-run 
healthcare systems that could be the final push that is required 
to move to universal healthcare under a single-payer? 
Access to Testing and Ventilation: Healthcare Trade-Offs
A final area to consider and on familiar grounds to health 
economists are issues related to access to testing and 
ventilation, where, despite obvious resource limitations, 
decisions do not seem to have been informed by economic 
appraisals. One would hope that, although not made explicit 
to the public, multi-layered cost-benefit calculations are going 
on in the policy background. Hence the priority we might 
give to symptomatic patients, healthcare and other frontline 
workers testing is expanded. But, with 1m workers in the UK’s 
NHS alone, testing would take several months to complete 
and, with reverse transcription polymerase chain reaction 
(RT-PCR) telling us only whether the virus is currently 
present, require repeat tests and all the laboratory resources 
that go with such testing. Surely analyses of incremental costs 
and health benefits of different roll-out strategies of testing 
would help maximise the benefit of this (obviously) scarce 
resource. The same applies to the additional antibody tests 
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which can tell whether a person has been infected in the 
past, but, apparently, and perhaps dangerously, with varying 
degrees of reliability.17 Careful analyses of trade-offs are 
required to ensure best use of this valuable resource, all in the 
name of ensuring gains in technical efficiency.
More drastically, issues about access to ventilation are 
beginning to emerge.18 Of course, governments are acting 
as fast as they can to ensure that ventilator capacity will be 
able to meet all the needs that may arise. Although, this may 
reflect public preferences for the ‘rule of rescue,’19 the heroic 
Nightingale and Louisa Jordan Hospitals in England and 
Scotland respectively may just be that, and, potentially, carry 
opportunity costs (ie, sacrifices) greater than benefits through 
diverting resources from social care and from other hospitals 
crying out for equipment, and even staff, in the very same 
cities. Difficult – and hopefully only occasional – choices of 
a cost-benefit nature will also arise, literally, at the bedside. 
Clinicians may be faced with deciding whether a young 
person with a decent chance of survival should take precedent 
over an older person who is severely ill and unlikely to live 
anyway. For those, we would want to rely on, and support, 
the experts – the clinicians. Speaking as health economists, 
we know we would. Likely, some level of ethical guidance is 
also required. Both economics and ethics would also seem 
to apply as issues of trading-off COVID-19 activities against 
non-COVID-19 treatments and procedures20 – sometimes for 
quite serious conditions – begin to emerge. Indeed tried-and-
tested, comprehensive frameworks for resource allocation, 
drawing on both ethics and economics, exist and could be 
playing a part.21 
Conclusion
The issues outlined above range from broad economic 
considerations to really quite specific trade-offs in ensuring 
maximum benefit for the population and best use of publicly-
funded resources. In all of this, health economic methods 
can make a major contribution, acknowledging of course 
health economics does not have all the answers. But there 
is a perspective and way of thinking outlined here that can 
be valuable when planning and seeking to make the best 
of this dynamic situation for society as a whole. Whether a 
matter of putting ourselves out there, being invited in or a 
combination of the two, greater visibility of health economics 
during the COVID-19 crisis will help, not just through the 
analyses provided but also in informing the major debates 
about allocation of society’s valuable resources that continue 
to ensue. That, likely more than anything, is the main reason 
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